Status: Not yet recruiting
ATR 1072 in Participants With PRKAG2 Syndrome
ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.
Participants needed: 37
Trial details
Phase: Phase 1, Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Atrium TherapeuticsUpdated: Jul 31, 2026
Eligibility criteria
Adults 18 to 65 years of age. [+4]
Pregnancy or breastfeeding. [+5]